PRÉNUMBRA

Class [005]
Pharmaceuticals for the prevention and treatment of vascular diseases and disorders; hemodynamic, vasoactive and anti-oncotic pharmaceutical drugs; pharmaceutical preparations for the prevention and treatment of cardiovascular, cerebrovascular and cardiopulmonary diseases and disorders; pharmaceuticals used for cerebrovascular accidents (strokes); cardiovascular treatment preparations; cardiovascular pharmaceuticals; cardiovascular pharmaceutical preparations; cardiovascular agents for medical purposes, namely, anti-oncotic therapeutic agents; cardiovascular drugs used in treating shocks; cardiovascular drugs used in myocardial infarctions; cardiovascular drugs used in treating arrhythmias; cardiovascular drugs used in angina pectoris; pharmaceutical preparations for the treatment of cardiovascular disease; cardiovascular drugs used in treating congestive heart failure (CHF); pharmaceutical preparations, preferably based on analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide; sun tanning preparations for pharmaceutical purposes, preferably based on analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide; pharmaceutical preparations for use in dermatology, namely, dermatitis, skin pigmentation diseases and treatment of acne; pharmaceutical preparations for treating the treatment of dermatological diseases and disorders, namely, skin and bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections, psoriasis, eczema and sexually transmitted diseases; dermatological preparations, namely, sunburn preparations for pharmaceutical purposes; dermatological pharmaceutical products, namely, dermatological preparations for the treatment of inflammatory skin diseases, dermatitis, psoriasis, vitiligo, eczema, sunburn, rash, rosacea, ichthyosis, urticaria, keratosis, pilaris and wounds; dermatological pharmaceutical products for the treatment of damaged skin and tissue, namely, bee stings, sunburn, rashes, sores, corns, calluses and acne; medicated creams for the protection of the skin, namely, medicated sun screen creams; medicated creams for skin care, namely, for the treatment of acne, sun damage, hyperpigmentation, hypopigmentation, dryness, redness, roughness, irritation, blotchiness, sagging and darkness of the skin; medicated skin care preparations containing analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide, namely, oils, ointments, serums, salves, balms, creams, lotions, and gels; medicated skin creams and lotions for the relief of pain; medicated creams for application after exposure to the sun for the treatment of skin irritations, namely sunburn, urticaria and rashes; pharmaceutical skin lotions for treating, reducing, and preventing lines, pores, and loss of skin firmness; preparations for cleansing the skin for medical use; chemical and biological preparations, substances, reagents and compounds for the delivery and storage of pharmaceuticals which are preferably based on analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide; afamelanotide aqueous and gel formulations.